Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration

Acta Ophthalmol. 2012 Dec;90(8):e647-8. doi: 10.1111/j.1755-3768.2012.02421.x. Epub 2012 Apr 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Bevacizumab
  • Female
  • Hallucinations / chemically induced*
  • Hallucinations / epidemiology
  • Humans
  • Incidence
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Syndrome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Wet Macular Degeneration / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab